Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
Merkel cell carcinoma is a rare but aggressive skin cancer. Response to chemotherapy is not durable but avelumab, an anti-PD-L1 inhibitor, showed promising ongoing response in a phase II trial. Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2019-08-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/502285 |
| _version_ | 1828489133129990144 |
|---|---|
| author | Sandy Tun Min Ina I.C. Nordman Huy A. Tran |
| author_facet | Sandy Tun Min Ina I.C. Nordman Huy A. Tran |
| author_sort | Sandy Tun Min |
| collection | DOAJ |
| description | Merkel cell carcinoma is a rare but aggressive skin cancer. Response to chemotherapy is not durable but avelumab, an anti-PD-L1 inhibitor, showed promising ongoing response in a phase II trial. Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAE). We describe the first reported case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic Merkel cell carcinoma on avelumab. Hypercalcaemia was managed with corticosteroids to full resolution and avelumab therapy was safely continued. |
| first_indexed | 2024-12-11T10:20:45Z |
| format | Article |
| id | doaj.art-18b514f1488f44799db1f64a153945bb |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-11T10:20:45Z |
| publishDate | 2019-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-18b514f1488f44799db1f64a153945bb2022-12-22T01:11:26ZengKarger PublishersCase Reports in Oncology1662-65752019-08-0112263964310.1159/000502285502285Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell CarcinomaSandy Tun MinIna I.C. NordmanHuy A. TranMerkel cell carcinoma is a rare but aggressive skin cancer. Response to chemotherapy is not durable but avelumab, an anti-PD-L1 inhibitor, showed promising ongoing response in a phase II trial. Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAE). We describe the first reported case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic Merkel cell carcinoma on avelumab. Hypercalcaemia was managed with corticosteroids to full resolution and avelumab therapy was safely continued.https://www.karger.com/Article/FullText/502285ImmunotherapyMerkel cell carcinomaAvelumabHypercalcaemiaSarcoidosis |
| spellingShingle | Sandy Tun Min Ina I.C. Nordman Huy A. Tran Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma Case Reports in Oncology Immunotherapy Merkel cell carcinoma Avelumab Hypercalcaemia Sarcoidosis |
| title | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| title_full | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| title_fullStr | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| title_full_unstemmed | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| title_short | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| title_sort | hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic merkel cell carcinoma |
| topic | Immunotherapy Merkel cell carcinoma Avelumab Hypercalcaemia Sarcoidosis |
| url | https://www.karger.com/Article/FullText/502285 |
| work_keys_str_mv | AT sandytunmin hypercalcaemiaduetosarcoidosisduringtreatmentwithavelumabformetastaticmerkelcellcarcinoma AT inaicnordman hypercalcaemiaduetosarcoidosisduringtreatmentwithavelumabformetastaticmerkelcellcarcinoma AT huyatran hypercalcaemiaduetosarcoidosisduringtreatmentwithavelumabformetastaticmerkelcellcarcinoma |